JACC. Case reports · 2025
A Case of Postural Orthostatic Tachycardia Syndrome in a 20-Year-Old Female Athlete: Review of Ivabradine Guidelines.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Boyapalli Samhitha, Alvarado Gerardo Aleman, Avanthsa Urvaksh, Nagi Alvin, Manouchehri Shaya, Testa Katie, Sumalbag Jericho, Pietras Richard J, Ben-Zur Uri M
Аннотация
BACKGROUND: Postural orthostatic tachycardia syndrome (POTS) is a disorder characterized by orthostatic intolerance, tachycardia, and syncope. Ivabradine, though not Food and Drug Administration approved for POTS, has shown promise in its management.
CASE SUMMARY: A 20-year-old woman with POTS, complicated by multiple comorbidities, experienced a severe functional decline. Standard therapies were ineffective. Given the presence of apical trabeculations and severe tachycardia, ivabradine was initiated, leading to rapid and sustained improvements in her symptoms.
DISCUSSION: This case highlights the effectiveness of ivabradine in patients with complex POTS who have failed conventional treatments. The patient's dramatic recovery underscores its potential to enhance quality of life. While previous studies support the efficacy of ivabradine in treating POTS, this case reinforces it as a viable treatment option and adds real-world evidence for its inclusion in treatment guidelines.
TAKE-HOME MESSAGE: As the understanding of POTS evolves, incorporating ivabradine into treatment guidelines could expand therapeutic options and improve patient outcomes, particularly in refractory cases.
CASE SUMMARY: A 20-year-old woman with POTS, complicated by multiple comorbidities, experienced a severe functional decline. Standard therapies were ineffective. Given the presence of apical trabeculations and severe tachycardia, ivabradine was initiated, leading to rapid and sustained improvements in her symptoms.
DISCUSSION: This case highlights the effectiveness of ivabradine in patients with complex POTS who have failed conventional treatments. The patient's dramatic recovery underscores its potential to enhance quality of life. While previous studies support the efficacy of ivabradine in treating POTS, this case reinforces it as a viable treatment option and adds real-world evidence for its inclusion in treatment guidelines.
TAKE-HOME MESSAGE: As the understanding of POTS evolves, incorporating ivabradine into treatment guidelines could expand therapeutic options and improve patient outcomes, particularly in refractory cases.